On Friday, May 13, India committed close to a million dollars to help create a benchmark document for training and practice of Ayurveda, Yoga, Unani, Siddha and Homeopathic medicine. It is indeed a significant commitment and the reinforcement of ongoing efforts by the World Health Organisation (WHO) to promote traditional health systems strengthening around the world.
What started with the Delhi declaration in 2012-13, with a consortium of South-East Asian countries is now slowly growing into an international collaboration. The Indian government used a country-by-country approach to sign bilateral agreements, starting with information centres in Mexico, Nepal, Malaysia, Russia among others. Continue reading
I’ve been quite vocal in my views about the ban on fixed dose combinations on Twitter. So here’s a selection of my key tweets (and some retweets) on the subject. Good way to get a quick summary of the subject while I hem and haw over a longer article (if it ever gets written). Latest tweets on top. Continue reading
The abnormally high margin that trade channels are believed to earn on a relatively small portion of the Indian pharmaceutical market has become the latest painpoint for the central government. The margins in question even cross 1000 per cent in some cases, according to a new report by a committee set up by the Department of Pharmaceuticals (DoP) in the Union Ministry of Chemicals and Fertilizers to investigate the matter.
The committee has now recommended capping trade margins on not just such meds which go by the moniker of ‘trade generics,’ but all drugs.
A cap on trade margins is not only difficult to implement but will do precious little to lower the price that the consumer pays. It might even lead to disputes and litigation between companies, trade, and the government. Besides, trade generics constitute not more than 15 per cent of the overall pharmaceutical market – and that is an outside estimate. Yet, this is being done in the name of the consumer. Continue reading
Last week, the Indian Express published my column on the urgent need for hospitals – big and small – to follow infection control norms. Click here to read.
While researching the column, I spoke to officials at the National Board for Accreditation of Hospitals and Healthcare Providers (NABH) to understand how the issue might be addressed. While hospital-acquired/associated infections (HAIs) have been a concern for some years now, the spectre of drug resistance makes addressing their occurrence that much more of an imperative. For that, hospitals need to take infection control seriously.
NABH, as its name suggests, sets up and operates accreditation programmes around quality-of-care at Indian hospitals. One of the things that piqued my interest was Safe-I, a handholding programme for hospitals, that is focused on infection control. Since 2012, NABH runs this in partnership with the healthcare company Becton Dickinson. Safe-I hopes to eventually become a robust source of HAI data through a network of participating hospitals. Excerpts from an e-mail interaction with NABH CEO Dr K K Kalra. Continue reading
The Competition Commission of India (CCI) recently slapped a Rs 63.5 crore fine collectively on GlaxoSmithKline Pharmaceuticals (GSK) and Sanofi Pasteur for attempting to collude to share a Union Ministry of Health tender for a meningitis vaccine and inflate prices. Indian health authorities have been immunising Indians performing Hajj, or the annual pilgrimage to Mecca, against meningitis since 2002. The case, which dates back to 2011, appears to be a great lesson in how not to tender.
What should’ve been a straightforward process for a single product with the same three suppliers year after year, took on the appearance of a farce with the tender being floated thrice over, more than one lawsuit, a disgruntled local producer and two vilified multinationals protesting their innocence. And to top it all, the guilt or lack of it of the Union Ministry of Health appears still open to question. Continue reading
A couple of weeks ago, I met senior executives from Bengaluru start-up PM Health & Life Care. The company is getting ready to fire off an online marketplace for prescription drugs that connects chemists to consumers. I was surprised with the timing; that they would choose to reach out when just a little before, the Maharashtra Food & Drugs Administration cracked down on Snapdeal for allowing vendors to sell drugs online. More on why they felt emboldened, later.
Intermediaries for online drug retail will have to shoulder a far greater responsibility for what passes through their channels than they would say, for clothes or shoes. Read why in this column that I wrote for Indian Express published today. And yet, given the far from well-governed nature of drug retail in the country – where drugs are routinely sold without prescription and laws flouted – the intermediary can only be as good as its partner on the ground. Continue reading
A recent article in the Indian Express reported statistics from India’s National Health Mission to highlight what it called “a debilitating shortage” of health specialists in the country. In doing so, it only reaffirmed what several experts, committees, and policy wonks have said all along: India needs more doctors.
For the longest time, India’s healthcare problem has been defined as one of numbers. Doctor demand outstrips supply, we are told. The accent has been on creating supply (predominantly in the private sector) to address this perceived shortage. I use the word “perceived” because the problem does not lie in numbers alone. What India faces is a full-blown leadership crisis caused by the systematic undermining of primary care physicians and the disproportionate clout wielded by super specialists in medical regulation against the backdrop of a lacklustre public health system. Continue reading
You can imagine the trepidation of a pharmaceutical company when the US Food & Drug Administration (FDA) comes calling. Given the demanding nature of inspections, recent enforcement actions and the public scrutiny that each warning letter is subjected to, even a battle-ready manufacturing site with the most stouthearted management can’t help but feel a ripple of nervous tension.
Now, consider the situation if the visit were wholly unexpected. Continue reading
The Indian Express edit page today carries a column I wrote on fixed dose combinations (FDCs) post the Lancet article. For the record, the Lancet shone the light on a plethora of FDCs of the diabetes drug metformin with others that, they believe, have no rationale to be on the market. I have used the FDCs issue as a springboard to comment on the larger state of drug regulation and call for its rehaul.
The Express is usually prompt in publishing my opinion pieces. This one, for some reason, they carried after several weeks of me having filed it. So those of you who are wondering why I chose to react to the Lancet article now, wonder no more.
If it sounds as if this piece of commentary would hold true in any year that is because, unfortunately for the Indian patient, some health issues never go out of fashion. Read on. The headline is a bit too dramatic for my taste but if that’s what it takes to grab eyeballs then so be it. I want to add here that I hope someone in New Delhi with the power to effect change is reading these pieces I do for the Express because they sure as hell aren’t reading my blog.
The media, it appears, cannot have enough of Dilip Shanghvi, the 60-year old founder and controlling stakeholder of Sun Pharmaceutical Industries. That’s not surprising if you consider that on March 4 he overtook Mukesh Ambani, the second-generation oil-to-telecoms tycoon and arguably India’s most influential businessman, to become the richest Indian.
Of course, just because Shanghvi went from number two to number one among wealthy Indians that day does not suddenly make him a new-improved version of himself nor does it throw up hitherto unknown facets of his personality (unless you go dig really deep and if you want to do that why wait for him to grow a shade wealthier, right?)
What it does, however, is generate curiosity. So when Outlook magazine reached out, my job was cut out for me. Here’s the link. Alternatively, you can click here and here for the PDF documents of the story as it appeared in the magazine, since the web edition seems to be missing some stuff.
The headline is not mine – as far as I am concerned, this ‘Sun’ arrived a while ago.
As an aside, this is the second time I’ve been warned by a commissioning editor to keep it simple. Do not badger the unsuspecting reader with big drug names, I was told categorically. (Seriously, I must be a pretentious bore). So I haven’t. That does not mean Shanghvi’s Sun Pharma does not make them. Try saying levetiracetam five times over without tripping over your tongue. Why? Because that barely pronounceable drug is one the reasons he upstaged Ambani.
Pic source : Sun Pharma
This post was altered to include more links to the article